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Abstract
Objective: Expression of the viral E6/E7 oncogenes of high-risk human papillomaviruses (HR-HPV) is necessary for malignant
conversion and maintenance in cervical tissue. In order to determine whether HR-HPV E6/E7 mRNA testing more effectively
predicts precancerous lesions and invasive cervical cancer than HR-HPV DNA testing, we aimed to compare triage using HR-
HPV E6/E7 mRNA testing by APTIMA HPV Assay (APTIMA) to HPV16 DNA testing, HPV16/18 DNA testing, and repeat
cytology.
Methods: Liquid-based (PreservCyt) cell samples were obtained from HR-HPV-positive women diagnosed with atypical
squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions (LSIL) within the
framework of the population-based cervical cancer screening program in Stockholm, Sweden. Samples were tested for HR-
HPV E6/E7 mRNA by APTIMA (Gene-Probe Inc., San Diego, CA, USA). Women were followed up for 4 years after the index
cytology via medical and laboratory records, and the Stockholm Oncology Center.
Results: Nine of 25 (36%) women in the ASCUS group, and 64 of 180 (36%) women in the LSIL group developed cervical
intraepithelial neoplasia (CIN) grade 2 or worse during 4 years of follow-up. 162 (74%) women were APTIMA-positive, and
APTIMA had the highest sensitivity to predict CIN2 or worse and CIN3 or worse in the ASCUS (77.8% and 100%) and LSIL
(78.1 and 75.8%) groups, although specificity was insufficient (,50%). HPV16 DNA testing and repeat cytology were more
specific than APTIMA.
Conclusion: The results of this population-based study with comprehensive follow-up support the use of APTIMA as a triage
test for women with ASCUS. More focused investigation is required for women with LSIL.
Citation: Persson M, Elfstro¨m KM, Brismar Wendel S, Weiderpass E, Andersson S (2014) Triage of HR-HPV Positive Women with Minor Cytological Abnormalities: A
Comparison of mRNA Testing, HPV DNA Testing, and Repeat Cytology Using a 4-Year Follow-Up of a Population-Based Study. PLoS ONE 9(2): e90023. doi:10.1371/
journal.pone.0090023
Editor: Anthony W.I. Lo, The Chinese University of Hong Kong, Hong Kong
Received December 19, 2013; Accepted January 24, 2014; Published February 26, 2014
Copyright:  2014 Persson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Swedish Cancer Foundation (070623, CAN 2007/1044; 110544, CAN 2011/471), Karolinska Institutet Cancer Strategic
Grants (5888/05-722), the Swedish Research Council (521-2008-2899), the Medical Research Council and the Cancer Society in Stockholm, the Stockholm County
Council. The study sponsors had no role in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; or in the
decision to submit the manuscript for publication.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sonia.andersson@karolinska.se
Introduction
Cytology-based cervical cancer screening programs have
significantly reduced the incidence and mortality of cervical
cancer [1,2]. Most abnormalities detected in cytological screening
are minor and non-specific. Cytology has a low positive predictive
value (PPV) for the detection of cervical intraepithelial neoplasia
(CIN) 2 or worse (CIN2+). There is also a high degree of inter-
observer variability in cytological assessment, resulting in highly
variable test accuracy [3–5].
Persistent infection with high-risk human papillomavirus (HR-
HPV) is a prerequisite for developing precancerous cervical lesions
and invasive cervical carcinoma (ICC) [6,7]. Women infected with
HPV16 and 18 are considered at particularly high risk and these
types account for approximately 70% of ICC worldwide [8]. The
relative risk of developing CIN2+ and CIN3 or worse (CIN3+)
among HPV16-positive women compared to women positive for
other HR-HPV types has been shown to be elevated (3.7 and 4.5,
respectively) [9].
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In Sweden today, approximately 8% of all cytological samples
show some kind of abnormality, 80% of which are minor (i.e.,
atypical squamous cells of undetermined significance (ASCUS) or
low-grade squamous intraepithelial lesions (LSIL)) [10]. According
to national recommendations from 2010, women with minor
cytological abnormalities should be referred for immediate
colposcopy, with cervical biopsies or should be triaged with
HPV DNA testing, preferable by reflex testing of a liquid-based
cytology sample [11]. However, repeat cytology is still used as a
follow-up method in some parts of Sweden.
Due to the high sensitivity (.90%) and negative predictive
value (NPV) of HR-HPV DNA testing to predict CIN, HPV triage
has become an attractive approach for the management of women
with ASCUS [12–15]. However, HPV triage is not recommended
in young women with LSIL, as the high prevalence of HR-HPV in
this group leads to poor specificity for HPV testing [13,14]. A test
that maximizes sensitivity and specificity would allow more
efficient and definitive triage.
HR-HPV infections results in progression to cervical cancer in
only a small percentage of infected women, after a long period of
latency. Thus, detection of mRNA transcripts of HPV genes
known to be involved in oncogenesis may be more useful for
detecting active and potentially persistent infection than HPV
DNA tests. The expression of viral E6/E7 oncogenes of HR-HPV
has been proposed as a marker of a transforming HPV infection
and relevant clinical progression of cervical disease [16–18]. Up-
regulation of these oncogenes triggers the degradation of p53 and
retinoblastomaprotein, which, in turn,causes deregulation of the
cell cycle, leading to malignant transformation [6]. Therefore,
HR-HPV E6/E7 mRNA is a promising marker to predict the
development of CIN2+ and ICC.
Studies of mRNA testing have shown consistently high
sensitivity and a higher specificity than HR-HPV DNA testing
both in primary screening and in ASCUS and LSIL triage
[14,19,20]. Since APTIMA always detects full-length E6/E7
mRNA, a positive result should correlate very well with integrated
HPV, loss of HPV replication, and stabilized E6/E7 full-length
mRNA expression.
The present longitudinal study aims to compare, for the first
time, the triage efficacy and usefulness of HR-HPV E6/E7 mRNA
testing of APTIMA HPV Assay (APTIMA) to that of HPV16
DNA testing, HPV16/18 DNA testing, and repeat cytology in the
population-based cervical cancer screening program.
Patients and Methods
Study Population
The study population was composed of 219 HR-HPV-positive
women diagnosed with ASCUS or LSIL within the framework of
the population-based cervical cancer screening program in
Stockholm, Sweden. Details on recruitment have been described
elsewhere [21]. Briefly, women with ASCUS or LSIL were
referred for further investigation, including colposcopy, directed
biopsies, and/or repeat cytology according to the screening
program guidelines. Histological samples were evaluated and
classified as within normal limits, CIN1, CIN2+ or CIN3+ based
on the most severe lesion present [22]. Cytological results were
classified according to the CIN classification of the Swedish
Society for Clinical Cytology [22], but were re-classified using the
Bethesda system for the purposes of this study, excluding
koilocytosis without nuclear atypia from the LSIL diagnosis [23].
The mean age of the study participants was 32.0 (range: 23–60
years (standard deviation (SD) 8.5 years)). Half of the women were
aged 30 years or younger and there was no statistically significant
difference in age between the ASCUS and LSIL groups (p = 0.60).
The mean age was 32.8 years (SD 9.0) and 31.9 years (SD 8.4) in
the ASCUS and LSIL groups, respectively. The age distribution of
the study participants was as follows: 25.1% were 23–24, 23.7%
were 25–29, 15.1% were 30–34, 16.0% were 35–39, 10.5% were
40–44, and 9.6% were 45–60 years of age. Women were followed
for 4 years after the index ASCUS/LSIL cytology, during which
time all histological and cytological results were obtained through
medical and laboratory records, and through the Stockholm
Oncology Center in cases where the information were insufficient.
Yearly follow-up of low-grade disease was performed according to
local clinical recommendations. Treatment by conization was
performed if low-grade disease persisted after two years or
immediately if high-grade disease was diagnosed.
HPV DNA Testing
HPV DNA testing had been previously performed on the
baseline ASCUS/LSIL samples from this study population. HPV
DNA was extracted (MagNA Pure LC robot, Roche Diagnostics,
Pleasanton, California, USA) from a lysed cell pellet of 1 milliliter
of the PreservCyt sample. The DNA of 37 HPV types [24] was
detected and genotyped by the Linear Array Genotyping Test
(Roche Diagnostics) according to the manufacturer’s instructions
[21]. Beta-globin was included in the test as an internal control to
test for sample adequacy and avoid false negatives.
HPV E6/E7 mRNA Testing by APTIMA
In the present study, PreservCyt samples used for HPV DNA
testing were retrieved from the archives and tested by APTIMA
(Gene-Probe Inc., San Diego, CA, USA). Samples were
transferred to 2.9 ml of buffered detergent solution and a 400 ml
aliquot of the mixture was then tested according to the
manufacturer’s instructions. APTIMA is a qualitative nucleic acid
amplification test that detects the E6/E7 mRNA of 14 HR-HPV
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68), and
has been validated for cervical specimens in PreservCyt medium
[25,26]. The test does not differentiate between HR-HPV types,
and is designed not to cross-react with low-risk HPV6, 11, 42, 43,
44, or probable HR-HPV 53. An analytic cut-off of 1.00 was used
to determine HPV interpretation. All laboratory analyses were
performed by the Department of Virology, Karolinska Hospital
[27].
Statistical Analysis
The most severe histological or cytological diagnosis recorded
during the 4-year follow-up was considered as the outcome.
Accuracy parameters for the prediction of CIN2+ and CIN3+
were computed for APTIMA, HPV16 DNA testing, HPV16/18
DNA testing, and repeat cytology. The parameters calculated
included: sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV), diagnostic odds ratio and
likelihood ratios (LR), stratified by ASCUS and LSIL diagnosis at
baseline. Relative sensitivities, specificities, PPV, and NPV with
95% confidence intervals (CIs) were computed for APTIMA
compared to HPV16 DNA testing, HPV16/18 DNA testing, and
repeat cytology at three different cut-off levels : ASCUS+, LSIL+
and high-grade squamous intraepithelial lesions or worse (HSIL+).
Analyses were performed using Stata 13 (Stata, College Station,
TX, USA).
Ethics Statement
This study was approved by the Regional Ethical Review Board
in Stockholm, Sweden (No. 04-679/3 and No. 2010/944-32) and
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written informed consent for all women were obtained before
inclusion.
Results
HR-HPV DNA and APTIMA Results at Index Cytology
With regard to the distribution of the index smears, LSIL
dominated (87.0%). All 219 women were HR-HPV DNA-positive
and HPV16 was the most frequently detected HPV type in the
ASCUS (20.7%) and LSIL groups (31.1%). The second most
common HPV type in the ASCUS group was HPV53 (17.2%),
while HPV51 and HPV52 were prevalent in the LSIL group
(15.3%). HPV18 was found in 13.8% of the ASCUS and 11.6% of
the LSIL group. In the ASCUS group, 31.0% were HPV16/18-
positive as compared to 41.1% of the LSIL group. In total, 162
women (74.0%) were mRNA positive with the APTIMA-test, 17
(58.6%) from the ASCUS and 145 (76.3%) from the LSIL group
(Table 1). The majority of HPV16/18-positive women were
APTIMA-positive, regardless of index cytology.
Cytological and Histological Results during Follow-up
Results for repeat cytology within 12 months were the following:
normal cytology was recorded in 113 (57.0%), ASCUS in 16
(8.1%), LSIL in 53 (26.3%), and atypical squamous cells-cannot
rule out high-grade lesions (ASC-H) in 17 (8.6%). Histopatholog-
ical results for 209 women during follow-up were missing in 8
(3.8%) women, not representative in 3 (1.4%), no CIN in 56
(26.8%), CIN1 in 69 (33.0%), CIN2 in 37 (17.7%), and CIN3+ in
36 (17.2%). Nine of 25 women in the ASCUS group (36.0%) and
64 of 180 (35.6%) women in the LSIL group developed CIN2+
during 4 years of follow-up.
Altogether, 205 women came for a follow-up visit within 12
months from the index cytology, whereof 198 had a repeat
cytology and, if indicated by colposcopy, a biopsy was taken.
Seven women had only a biopsy test result available. Four women
came for follow-up visits later than 12 months and therefore their
cytological test result could not be categorized as a repeat cytology.
Ten women were lost to follow-up for unknown reasons. The
characteristics of those that were lost to follow-up did not differ
largely from the women that were followed, although the mean
age was 30.3 years (slightly younger).
Accuracy of Different Triage Options in the ASCUS Group
The sensitivity of APTIMA to predict CIN2+ and CIN3+ was
77.8% (95% CI 40.0–90.0) and 100.0% (95% CI 40.0–100),
respectively in the ASCUS group. Specificity to predict the
absence of CIN2+ or CIN3+ was 50.0% (CI 30.0–70.0) and
45.5% (CI 30.0–60.0), respectively (Figure 1, Table 2).
APTIMA was the most sensitive test for triage in the ASCUS
group, but the difference reached statistical significance only when
compared with repeat cytology using a cut-off of HSIL+ to predict
CIN2+ (relative sensitivity 7.0, CI 1.1–45.9). APTIMA was
significantly less specific than HPV16 DNA testing to predict
CIN2+ and CIN3+ (relative specificity 0.6 (CI 0.3–0.9) and 0.6 (CI
0.3–0.9), respectively) and significantly less specific than repeat
cytology using a cut-off of LSIL+ and HSIL+ to predict CIN3+
(0.6 (CI 0.3–0.9) and 0.4 (CI 0.3–0.7)) (Table 3).
Table 1. Type-specific HPV DNA distribution in the ASCUS and LSIL groups by APTIMA status.
ASCUS group LSIL group
APTIMA2 APTIMA+ APTIMA2 APTIMA+
type N row % N row% N row % N row%
16 2 33.3% 4 66.7% 16 22.5% 55 77.5%
18 0 0.0% 4 100.0% 6 25.0% 18 75.0%
31 1 25.0% 3 75.0% 2 7.7% 24 92.3%
33 2 50.0% 2 50.0% 3 25.0% 9 75.0%
35 0 – 0 – 4 23.5% 13 76.5%
39 1 50.0% 1 50.0% 4 16.7% 20 83.3%
45 0 0.0% 1 100.0% 5 20.0% 20 80.0%
51 3 75.0% 1 25.0% 4 12.5% 28 87.5%
52 1 50.0% 1 50.0% 7 20.0% 28 80.0%
56 0 0.0% 3 100.0% 1 4.3% 22 95.7%
58 2 50.0% 2 50.0% 2 15.4% 11 84.6%
59 0 0.0% 1 100.0% 2 10.0% 18 90.0%
66 1 33.3% 2 66.7% 0 0.0% 18 100.0%
68 0 0.0% 2 100.0% 3 37.5% 5 62.5%
26 0 – 0 – 1 50.0% 1 50.0%
53 1 20.0% 4 80.0% 5 25.0% 15 75.0%
73 1 50.0% 1 50.0% 6 27.3% 16 72.7%
82 0 0.0% 3 100.0% 0 – 0 –
16/18 2 22.2% 7 77.8% 22 23.7% 71 76.3%
Total 12 41.4% 17 58.6% 45 20.6% 145 79.4%
HPV: human papillomavirus, ASCUS: atypical squamous cells of undetermined significance, LSIL: low-grade squamous intraepithelial lesions.
doi:10.1371/journal.pone.0090023.t001
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The PPV for all test options ranged from 29.4–100.0% for
CIN2+ and from 12.5–100.0% for CIN3+. The PPV of APTIMA
(46.7% (95% CI 24.8–69.9) for CIN2+ and 20.0% (95% CI 7.0–
45.2) for CIN3+ was lower than that of the other tests, with the
exception of repeat cytology using a cut-off of ASCUS+ to predict
CIN2+ (29.4%, 95% CI 13.3–53.1), and HPV 16/18 DNA testing
to predict CIN3+ (12.5%, 95% CI 2.2–47.1), but the differences
were not significant. The relative PPV of APTIMA compared to
repeat cytology using a cut-off of HSIL+ was 0.5 (CI 0.3–0.8) to
predict CIN2+ and 0.2 (CI 0.1–0.6) to predict CIN3+ (Table 4)
which were significant.
The risk of disease following a negative triage test result
(calculated as the complement of the NPV: cNPV=1-NPV)
ranged from 5.3–11.8% for the outcome CIN3+, with the
exception of APTIMA, for which no risk was detected. A negative
APTIMA test resulted in a lower risk of disease compared to the
other tests, but the difference was only significant when compared
to repeat cytology using a cut-off of LSIL+ and HSIL+ (relative
cNPV 0.6, CI 0.4–0.9 and 0.6, CI 0.4–0.9, for LSIL+ and HSIL+
respectively).
Accuracy of Different Triage Options in the LSIL Group
The sensitivity of APTIMA was 78.1% (95% CI 70.0–90.0 and
75.8% (95% CI 60.0–90.0) for predicting CIN2+ and CIN3+,
respectively, in the LSIL group. The specificity for predicting the
absence of CIN2+ and CIN3+ was 25.0% (95% CI 20.0–30.0) and
23.8% (95% CI 20.0–30.0), respectively (Table 2). APTIMA was
significantly more sensitive for predicting CIN2+ and CIN3+
compared to all other tests, except HPV16/18 DNA testing to
predict CIN3+, where the difference between APTIMA and
HPV16/18 DNA testing was not significant (Table 3). However,
APTIMA was significantly less specific compared to all the other
tests.
PPVs ranged from 36.5–76.9% for CIN2+ and from 18.2–
46.2% for CIN3+. The PPV of APTIMA was lower than the other
tests, but this was only significant when compared with repeat
Figure 1. Sensitivity & FPR (False positive rate) of the different tests used to triage women with ASCUS (upper) or LSIL (lower) to
detect CIN2+ (left) or CIN3+ (right). Red circle: APTIMA, rhombus without color HPV DNA 16, rhombus blue HPV16/18 DNA, cross: cytology AS-
CUS as cut-off, diagonal cross: cytology with LSIL as cut-off, double diagonal cross: cytology with HSIL as cut-off. ASCUS-atypical squamous cells of
undetermined significance, LSIL-low-grade squamous intraepithelial lesions, HSIL2 high-grade squamous intraepithelial lesions. CIN2 cervical
intraepithelial neoplasia. HR-HPV: High-risk human papillomavirus.
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cytology using a cut-off of HSIL+, where the relative PPV was 0.5
(CI 0.3–0.7) for CIN2+ and 0.4 (CI 0.2–0.8) for CIN3+.
The risk of disease was still high when triage tests were negative
(cNPV ranged from 28.0–32.7% for CIN2+ and from 14.0–18.6%
for CIN3+.). A negative APTIMA test did not result in or predict a
decrease in the risk of disease compared to other tests, and the risk
of CIN3+ was significantly higher for APTIMA negative women
compared to negative HPV16 DNA, HPV16/18 DNA, or repeat
cytology result using a cut-off of ASCUS+.
Most tests showed accuracy estimates that did not deviate
strongly from the neutral diagonal line (LR+ and LR2 near 1),
indicating poor triage capacity (Figure 1).
Discussion
HPV infection is a necessary factor in the etiology of ICC [6]
and expression of the viral E6/E7 oncogenes is necessary for
conversion to and maintenance of malignancy in cervical tissue.
HPV testing is an excellent first screen to identify women with a
higher risk of developing cervical cancer. However, as known
HPV testing has only limited power to stratify low-grade from
high-grade disease and can therefore not be used to efficiently
triage patients further. Therefore, additional markers for triaging
patients to avoid overtreatment and overlooking relevant lesions
are needed. Potential triage markers tested in this study were HPV
mRNA expression, HPV 16 DNA, HPV 16/18 DNA and
repeated cytology.
In the current study, APTIMA detected 100% of CIN3+ and
77.8% of CIN2+ in the ASCUS group. APTIMA was the most
sensitive test to predict high-grade CIN compared to HPV16
DNA testing, HPV16/18 DNA testing, and repeat cytology at
three different cut-off levels. The specificity of APTIMA to exclude
CIN2+ in the ASCUS group was 50.0%, and the PPV was 46.7%.
HPV DNA testing is widely accepted for ASCUS triage due to
its higher sensitivity and similar specificity compared to repeat
cytology (12), but newer assays like RNA-based APTIMA have
also shown good performance in ASCUS triage (due to its higher
specificity) [33]. Our results were similar to those of a meta-
analysis of ASCUS triage, in which APTIMA maintained high
sensitivity, but showed a greater specificity to detect cervical
disease compared to Hybrid Capture 2 [33]. While the sensitivity
of APTIMA was higher, in our study HPV16 DNA testing
(specificity 87.5%) was significantly more specific. HPV 16 DNA
testing identified women at the highest risk for cervical disease
(PPV for CIN2+60.0%), but the sensitivity was low (33.3%). The
30% risk of disease, despite a negative HPV16 DNA result,
Table 2. Overview of the sensitivity and specificity, PPV, NPV, the risk of diseasea in case of a negative test (cNPV-1-NPV), DOR and
LR.
Triage
group Outcome Test
Test
cut-off TP FN FP TN N Sensitivity Specificity PPV NPV cNPV DOR LR+ LR–
ASCUS CIN2+ APTIMA + 7 2 8 8 25 77.8% 50.0% 46.7% 80.0% 20.0% 5.60 1.56 0.44
ASCUS CIN2+ HPV16 DNA + 3 6 2 14 25 33.3% 87.5% 60.0% 70.0% 30.0% 5.25 2.67 0.76
ASCUS CIN2+ HPV16/18 DNA + 4 5 4 12 25 44.4% 75.0% 50.0% 70.6% 29.4% 5.33 1.78 0.74
ASCUS CIN2+ Repeat cytology ASCUS+ 5 4 12 4 25 55.6% 25.0% 29.4% 50.0% 50.0% 1.25 0.74 1.78
ASCUS CIN2+ Repeat cytology LSIL+ 3 6 3 13 25 33.3% 81.3% 50.0% 68.4% 31.6% 4.33 1.78 0.82
ASCUS CIN2+ Repeat cytology HSIL+ 1 8 0 16 25 11.1% 100.0% 100.0% 66.7% 33.3% 2.00 – 0.89
ASCUS CIN3+ APTIMA + 3 0 12 10 25 100.0% 45.5% 20.0% 100.0% 0.0% 2.50 1.83 0.00
ASCUS CIN3+ HPV16 DNA + 1 2 4 18 25 33.3% 81.8% 20.0% 90.0% 10.0% 3.00 1.83 0.81
ASCUS CIN3+ HPV16/18 DNA + 1 2 7 15 25 33.3% 68.2% 12.5% 88.2% 11.8% 1.67 1.05 0.98
ASCUS CIN3+ Repeat cytology ASCUS+ 2 1 7 15 25 66.7% 68.2% 22.2% 93.8% 6.3% 3.75 2.10 0.49
ASCUS CIN3+ Repeat cytology LSIL+ 2 1 4 18 25 66.7% 81.8% 33.3% 94.7% 5.3% 7.20 3.67 0.41
ASCUS CIN3+ Repeat cytology HSIL+ 1 2 0 22 25 33.3% 100.0% 100.0% 91.7% 8.3% 11.00 – 0.67
LSIL CIN2+ APTIMA + 50 14 87 29 180 78.1% 25.0% 36.5% 67.4% 32.6% 14.36 1.04 0.88
LSIL CIN2+ HPV16 DNA + 24 40 32 84 180 37.5% 72.4% 42.9% 67.7% 32.3% 28.00 1.36 0.86
LSIL CIN2+ HPV16/18 DNA + 29 35 44 72 180 45.3% 62.1% 39.7% 67.3% 32.7% 26.43 1.19 0.88
LSIL CIN2+ Repeat cytology ASCUS+ 34 30 39 77 180 53.1% 66.4% 46.6% 72.0% 28.0% 37.94 1.58 0.71
LSIL CIN2+ Repeat cytology LSIL+ 27 37 33 83 180 42.2% 71.6% 45.0% 69.2% 30.8% 32.01 1.48 0.81
LSIL CIN2+ Repeat cytology HSIL+ 10 54 3 113 180 15.6% 97.4% 76.9% 67.7% 32.3% 19.82 6.04 0.87
LSIL CIN3+ APTIMA + 25 8 112 35 180 75.8% 23.8% 18.2% 81.4% 18.6% 7.29 0.99 1.02
LSIL CIN3+ HPV16 DNA + 15 18 41 106 180 45.5% 72.1% 26.8% 85.5% 14.5% 26.95 1.63 0.76
LSIL CIN3+ HPV16/18 DNA + 18 15 55 92 180 54.5% 62.6% 24.7% 86.0% 14.0% 23.66 1.46 0.73
LSIL CIN3+ Repeat cytology ASCUS+ 17 16 56 91 180 51.5% 61.9% 23.3% 85.0% 15.0% 21.49 1.35 0.78
LSIL CIN3+ Repeat cytology LSIL+ 13 20 47 100 180 39.4% 68.0% 21.7% 83.3% 16.7% 19.40 1.23 0.89
LSIL CIN3+ Repeat cytology HSIL+ 6 27 7 140 180 18.2% 95.2% 46.2% 83.8% 16.2% 24.71 3.82 0.86
PPV, positive predictive value, NPV: negative predictive value, DOR: diagnostic odds ratio, LR: likelihood ratio, TP: true positive, FN: false negative, FP: false positive, TN:
true negative, N: number, ASCUS: atypical squamous cells of undetermined significance, CIN2+: cervical intraepithelial neoplasia grade 2 or worse, HPV: human
papillomavirus, LSIL: low-grade squamous intraepithelial lesions, CIN3+: cervical intraepithelial neoplasia grade 3 or worse.
ahe risks of disease cNPV= 1-NPV.
doi:10.1371/journal.pone.0090023.t002
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indicated that these women cannot return to the normal screening
schedule. Compared to HPV16 DNA testing, repeat cytology
using a cut-off of LSIL+ yielded a low sensitivity, but an equally
high specificity to detect high-grade CIN.
APTIMA-negative women in the ASCUS group had the lowest
risk of disease, and no risk for CIN3+ was found. In the LSIL
group, APTIMA was the most sensitive test, detecting 76% and
78% of all CIN3+ and CIN2+, respectively, but the least specific
test (24–25% for detecting CIN3+ and CIN2+). Specificity for
CIN3+ might not be considered useful in a clinical setting, as it
would consider CIN2 results false-positives, which is not appro-
priate as most screening programs use CIN2 as the cut-off for
treatment [28].
Our results are lower than the pooled sensitivity (91.0% and
96.7%) and specificity (42.5% and 38.7%) of APTIMA to detect
CIN2+ and CIN3+ among LSILs reported in the aforementioned
meta-analysis [33], which concluded that APTIMA might also be
considered for LSIL triage. Other studies have also demonstrated
difficulties with specificity in the LSIL group [29]. HPV DNA
testing has not been recommended for LSIL triage because of its
low specificity due to the high prevalence of HPV, especially in
younger age groups. Fifty percent of our study women were under
30 years of age, which may have contributed to the observed low
specificity, as lesions in young women may be more prone to
regress. The use of CIN2+ as an outcome has also been an area of
discussion, since the reproducibility of the diagnosis is considered
poor [30]. A re-evaluation of the evidence for HPV66 [31] has
revealed it to be a relatively common type, though it is rarely
found in cancer, which could decrease the specificity and PPV of
an assay that includes this type [31]. HPV66 is included in
APTIMA, which may also have contributed to the low specificity.
A limitation of this study could be that specimens were stored
for up to 5 years at room temperature in PreservCyt medium
before APTIMA testing, as longer storage times might lead to
mRNA degradation. However, two other studies have used
PreservCyt specimens that had been stored for more than 3 years
[29,32] and concluded that mRNA was well preserved. We have
investigated the use of APTIMA on samples from women
undergoing testing for cervical cancer in a population-based
routine screening program, reflecting a real-life setting and
allowing us to apply our findings directly to routine clinical
practice.
Strengths of the present study are the case verification and the
data quality of the follow-up, based on unique personal
identification numbers as part of the organized screening program
and register via medical records and in cases with insufficient
information data were supplemented with information from the
Stockholm Oncology Center. The long observation time covers an
entire 3-year screening interval which allows us to comment on the
performance of the triage tests within the context of a program-
matically relevant follow-up period.
Previous studies have compared the APTIMA test with the
PreTect HPV-Proofer mRNA test (Norchip AS, Klokkarstua,
Oslo, Norway) in women with ASCUS or LSIL cytology. The
PreTect test detects mRNA of five HR-HPV types (16, 18, 31, 33,
and 45). APTIMA was substantially more sensitive (ratio 1.91
Table 3. Relative sensitivity and specificity of APTIMA compared to other tests to triage women with ASCUS or LSIL for the
outcomes CIN2+ or CIN3+a.
Relative sensitivity Relative specificity
Triage group Outcome Test Estimate lower CIB upper CIB Estimate lower CIB upper CIB
ASCUS CIN2+ HPV16 DNA 2.33 0.87 6.27 0.57 0.34 0.96
ASCUS CIN2+ HPV6/18 DNA 1.75 0.78 3.93 0.67 0.38 1.17
ASCUS CIN2+ Cyto at ASCUS+ 1.40 0.71 2.77 2.00 0.75 5.33
ASCUS CIN2+ Cyto at LSIL+ 2.33 0.87 6.27 0.62 0.36 1.06
ASCUS CIN2+ Cyto at HSIL+ 7.00 1.07 45.90 0.50 0.31 0.82
ASCUS CIN3+ HPV16 DNA 3.00 0.61 14.86 0.56 0.34 0.91
ASCUS CIN3+ HPV16/18 DNA 3.00 0.61 14.86 0.67 0.39 1.14
ASCUS CIN3+ Cyto at ASCUS+ 1.50 0.67 3.34 0.67 0.39 1.14
ASCUS CIN3+ Cyto at LSIL+ 1.50 0.67 3.34 0.56 0.34 0.91
ASCUS CIN3+ Cyto at HSIL+ 3.00 0.61 14.86 0.45 0.29 0.72
LSIL CIN2+ HPV16 DNA 2.08 1.48 2.93 0.35 0.25 0.48
LSIL CIN2+ HPV16/18 DNA 1.72 1.28 2.32 0.40 0.29 0.57
LSIL CIN2+ Cyto at ASCUS+ 1.47 1.13 1.92 0.38 0.27 0.53
LSIL CIN2+ Cyto at LSIL+ 1.85 1.35 2.54 0.35 0.25 0.49
LSIL CIN2+ Cyto at HSIL+ 5.00 2.79 8.97 0.26 0.19 0.35
LSIL CIN3+ HPV16 DNA 1.67 1.09 2.54 0.33 0.24 0.45
LSIL CIN3+ HPV16/18 DNA 1.39 0.96 2.00 0.38 0.28 0.52
LSIL CIN3+ Cyto at ASCUS+ 1.47 1.00 2.16 0.38 0.28 0.53
LSIL CIN3+ Cyto at LSIL+ 1.92 1.21 3.06 0.35 0.26 0.48
LSIL CIN3+ Cyto at HSIL+ 4.17 1.97 8.81 0.25 0.19 0.33
HPV: human papillomavirus, ASCUS: typical squamous cells of undetermined significance, LSIL: low-grade squamous intraepithelial lesions, CIB: 95% confidence interval
bound.
aSignificant differences in bold.
doi:10.1371/journal.pone.0090023.t003
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(95% CI: 1.43–2.56) but less specific (ratio: 0.47 (95% CI: 0.34–
0.63) for CIN2+) [33–35]. Rijkaart et al investigated whether HR-
HPV mRNA detection by the PreTect HPV-Proofer can be used
as a reflex test to stratify HR-HPV DNA-positive women of
different cytological diagnoses for risk of CIN2+. The results
showed that a positive PreTect HPV-Proofer reflex test conferred
an increased risk of CIN2+ in HR-HPV DNA-positive women,
particularly for those with normal cytology [36].
In summary, the tests evaluated showed accuracy estimates that
indicated poor LSIL triage capacity, and the risk of disease
remained even when triage tests were negative, indicating that
these women cannot return to routine screening. In LSIL triage,
our results suggested that, using a cut-off of ASCUS+, a negative
HPV16 DNA, HPV16/18 DNA, or cytology resulted in lower
risks of CIN over follow-up as compared to a negative APTIMA
result. APTIMA showed only a limited ability to stratify the LSIL
group according to disease risk, and therefore cannot be used to
efficiently triage women with LSIL. Additional markers that can
effectively triage these women and avoid over-treatment while not
overlooking relevant lesions are needed. In the present study,
APTIMA predicted 100% of CIN3+ and 77.8% of CIN2+ in the
ASCUS group, making it the most sensitive test for detecting
underlying high-grade cervical lesions. This corroborates existing
data that APTIMA is an excellent test to identify those women
with ASCUS who have a higher risk of developing high grade
lesions and ICC.
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